Biocryst Pharmaceuticals (BCRX) Interest Expenses (2011 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Interest Expenses came in at $71.0 million in Q1 2026, up 202.25% YoY from $23.5 million in Q1 2025, and up 402.37% on a QoQ basis from $14.1 million in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Interest Expenses (2011 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 16 years of Interest Expenses data on file, last reported at $71.0 million in Q1 2026.
- Quarterly Interest Expenses rose 202.25% year-over-year to $71.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $71.0 million (down 27.17% YoY) and the FY2025 annual result came in at $380.5 million, down 15.2% from the prior year.
- Interest Expenses climbed to $71.0 million in Q1 2026, from $14.1 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $91.1 million in Q4 2023 to a low of $14.1 million in Q4 2025.
- A 5-year average of $31.3 million and a median of $24.8 million in 2022 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2023 — Interest Expenses soared 244.27% — and 2024, when it slumped 73.16%.
- Tracing BCRX's Interest Expenses over 5 years: stood at $26.5 million in 2022, then soared by 244.27% to $91.1 million in 2023, then tumbled by 73.16% to $24.4 million in 2024, then slumped by 42.19% to $14.1 million in 2025, then jumped by 402.37% to $71.0 million in 2026.
- The last three Interest Expenses figures came in at $71.0 million (Q1 2026), $14.1 million (Q4 2025), and $29.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | -400.56 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 2.90 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 120.70 Mn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 2.90 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | 59.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.47 Bn | 2.12 Bn | 214.41 Mn | 21.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 80.24 Mn |
| Jun 30, 2026 | 80.24 Mn |
| Mar 31, 2026 | 71.01 Mn |
| Mar 31, 2026 | 71.01 Mn |
| Dec 31, 2025 | 14.14 Mn |
| Dec 31, 2025 | 14.14 Mn |
| Sep 30, 2025 | 28.97 Mn |
| Sep 30, 2025 | 28.97 Mn |
| Jun 30, 2025 | 21.58 Mn |
| Jun 30, 2025 | 21.58 Mn |
| Mar 31, 2025 | 23.49 Mn |
| Mar 31, 2025 | 23.49 Mn |
| Dec 31, 2024 | 24.45 Mn |
| Dec 31, 2024 | 24.45 Mn |
| Sep 30, 2024 | 24.83 Mn |
| Sep 30, 2024 | 24.83 Mn |
| Jun 30, 2024 | 24.73 Mn |
| Jun 30, 2024 | 24.73 Mn |
| Mar 31, 2024 | 24.51 Mn |
| Mar 31, 2024 | 24.51 Mn |